Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
L&C Bio Co., Ltd (290650.KQ)
KRW68,900.00
-600.00 (-0.86%)
KR KOE Healthcare Medical - Specialties
Address
Suntechcity 13229
Seongnam-si, KR
Seongnam-si, KR
CEO
Chul Lee Whan
Website
lncbio.co.kr
IPO
2018-11-01
ISIN KR7290650001
Description
Specializing in regenerative tissue medicine, L&C BIO Co., Ltd. operates as a dedicated research and development enterprise. The company's diverse product range encompasses human tissue products, various medical devices, and a selection of cosmetic solutions. Established in 2011, this firm is headquartered in Seongnam, South Korea.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW68,900.00
-600.00 (-0.86%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
343.0K
Beta
1.38
Float Shares
17.50M
Free Float %
72.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13% | +8.29% | +19.94% | -23.12% | +30.69% | +21.47% | +168.79% | +123.60% | +146.50% | +743.79% | +743.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
68,900.00
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | +1 |
| Buy | 1 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.70
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+18.6% ★ Q1'26: +70.6% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-201.5% Q1'26: +655.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+20.6% Q1'26: +2.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+4.0% Q1'26: +19.8% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+1.3% Q1'26: +8.6% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%-2.3% ★ Q1'26: +14.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×7.97× Q1'26: 2.70× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
21.24B
est: 23.55B (-9.8%)
|
29.15B
est: 29.15B (+0.0%)
|
32.97B
est: 33.90B (-2.7%)
|
45.68B
est: 45.00B (+1.5%)
|
52.57B
est: 63.00B (-16.6%)
|
68.87B
est: 69.70B (-1.2%)
|
72.09B
est: 74.70B (-3.5%)
|
85.48B
est: 85.70B (-0.3%)
|
148.61B
143.55B – 153.67B
+73.4% YoY
|
288.87B
227.76B – 332.60B
+94.4% YoY
|
343.78B
292.95B – 381.35B
+19.0% YoY
|
1.03T
878.73B – 1.14T
+200.0% YoY
|
| EBITDA |
6.39B
est: 10.14B (-36.9%)
|
11.07B
est: 12.55B (-11.8%)
|
9.90B
est: 14.59B (-32.1%)
|
16.71B
est: 19.37B (-13.7%)
|
14.25B
est: 27.11B (-47.4%)
|
14.78B
est: 30.00B (-50.7%)
|
147.77B
est: 29.68B (+397.8%)
|
11.57B
est: 34.06B (-66.0%)
|
59.05B
57.04B – 61.06B
+73.4% YoY
|
114.79B
90.51B – 132.17B
+94.4% YoY
|
136.61B
116.41B – 151.54B
+19.0% YoY
|
409.78B
349.19B – 454.56B
+200.0% YoY
|
| EBIT |
5.91B
est: 8.70B (-32.1%)
|
9.98B
est: 10.77B (-7.3%)
|
8.31B
est: 12.53B (-33.6%)
|
13.81B
est: 16.63B (-16.9%)
|
8.45B
est: 23.28B (-63.7%)
|
9.12B
est: 25.76B (-64.6%)
|
141.01B
est: 24.44B (+477.0%)
|
3.44B
est: 28.04B (-87.7%)
|
48.62B
46.96B – 50.27B
+73.4% YoY
|
94.50B
74.51B – 108.81B
+94.4% YoY
|
112.47B
95.84B – 124.76B
+19.0% YoY
|
337.36B
287.48B – 374.23B
+200.0% YoY
|
| Net Income |
5.21B
est: 7.05B (-26.1%)
|
7.25B
est: 8.31B (-12.7%)
|
10.81B
est: 9.47B (+14.2%)
|
13.81B
est: 8.62B (+60.3%)
|
4.54B
est: 12.32B (-63.1%)
|
48.36B
est: 17.66B (+173.9%)
|
141.06B
est: 2.24B (+6,196.6%)
|
-138.17B
est: -134.99B (-2.4%)
|
11.62B
9.21B – 14.03B
+108.6% YoY
|
56.54B
44.44B – 68.65B
+386.4% YoY
|
69.14B
55.85B – 78.96B
+22.3% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
4.76B
est: 6.44B (-26.1%)
|
5.70B
est: 7.98B (-28.5%)
|
9.55B
est: 9.28B (+3.0%)
|
12.06B
est: 12.31B (-2.1%)
|
13.94B
est: 17.24B (-19.1%)
|
20.48B
est: 19.07B (+7.4%)
|
18.17B
est: 20.12B (-9.7%)
|
22.91B
est: 23.08B (-0.7%)
|
40.02B
38.66B – 41.38B
+73.4% YoY
|
77.79B
61.33B – 89.57B
+94.4% YoY
|
92.58B
78.89B – 102.70B
+19.0% YoY
|
277.70B
236.64B – 308.05B
+200.0% YoY
|
| EPS |
276.67
est: 279.83 (-1.1%)
|
331.03
est: 329.78 (+0.4%)
|
493.83
est: 376.00 (+31.3%)
|
619.55
est: 342.00 (+81.2%)
|
200.32
est: 489.00 (-59.0%)
|
2,132.00
est: 701.00 (+204.1%)
|
6,219.11
est: 91.00 (+6,734.2%)
|
-5,811.40
est: -5,483.00 (-6.0%)
|
472.15
374.29 – 570.02
+108.6% YoY
|
2,296.71
1,805.04 – 2,788.39
+386.4% YoY
|
2,808.36
2,268.56 – 3,207.35
+22.3% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
20.27B
OE per share TTM
814.86
Owner's Yield
1.03%
Maintenance CapEx ratio
165.81%
Maint CapEx / Avg PPE
94.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
26.89M
Shares Outstanding
24.32M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chul Lee Whan | Chief Executive Officer | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 290650.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
